Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tirabrutinib as monotherapy in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia | Phase 1 | Status: COMPLETED | Results posted: 2021-01-28